A high proportion of patients in our cohort defined on clinical grounds as having incomplete SLE eventually showed disease activity defined by the SLEDAI as well as ECLAM. However, only three cases developed to SLE during the follow-up. This suggests that incomplete SLE forms a subgroup of SLE that has a good prognosis.

After 11 years, initial COBRA combination therapy resulted in numerically lower mortality and similar prevalence of comorbidity compared with initial SSZ monotherapy. In addition, lower progression of joint damage suggests long-term disease modification.

Vol. 9 -I987 Pharmaceutisch Weekblad Scienttfic Edition officinale L. species complex and S. asperum Lepech. Part n. Phytosterols and triterpe.noids. Plant Syst Evol z983;I43:285-92. Wichers H J, Ten Kate J, Buys CHCM, Huizing HJ. A simple and rapid procedure to obtain nucleated proto-z87 plasts from plant material. Cytologia I984;49: xo3-9. Huizing H J, R6der E, Wiedenfeld H. Die '~C-NMR-Daten des Pyrrolizidine-Alkaloids Echimidin. Arch Pharm (Weinheim) *985;3*8:476-7. clinical pharmacological meeting Organized by the